Physician profile
Norman Robert Willis
NPI 1508854290
$4,815.48
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $523 · 2021: $903 · 2022: $1,469 · 2023: $891 · 2024: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $381.72 | 2019-2023 | Blincyto, Kyprolis, Vectibix |
| Glaxosmithkline, LLC. | $356.35 | 2020-2023 | Zejula |
| Merck Sharp & Dohme LLC | $318.54 | 2020-2024 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $302.69 | 2019-2022 | |
| Seagen INC. | $269.88 | 2019-2023 | Adcetris |
| Novartis Pharmaceuticals Corporation | $267.33 | 2021-2024 | |
| Janssen Biotech, INC. | $258.56 | 2020-2024 | Erleada, Tremfya |
| Bayer Healthcare Pharmaceuticals INC. | $199.53 | 2019-2023 | |
| Genzyme Corporation | $196.45 | 2019-2023 | |
| Astellas Pharma US INC | $195.93 | 2019-2022 | |
| Genentech USA, INC. | $137.72 | 2019 | |
| Lilly USA, LLC | $136.79 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Accuray Incorporated | $121.67 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.08 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $119.88 | 2022-2023 | Rezlidhia, Tavalisse |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.